LncRNA CANT1 is a novel tumor suppressor in uveal melanoma and activates a novel CANT1-JPX/FTX-XIST long noncoding pathway by directly binding to the promoters of lncRNAs JPX and FTX and restoring the histone H3K4 methylation of their promoters15. The gene discussed is FTX; the disease is uveal melanoma.